238 related articles for article (PubMed ID: 33138349)
1. Upregulated N6-Methyladenosine RNA in Peripheral Blood: Potential Diagnostic Biomarker for Breast Cancer.
Xiao H; Fan X; Zhang R; Wu G
Cancer Res Treat; 2021 Apr; 53(2):399-408. PubMed ID: 33138349
[TBL] [Abstract][Full Text] [Related]
2. Changes of N6-methyladenosine modulators promote breast cancer progression.
Wu L; Wu D; Ning J; Liu W; Zhang D
BMC Cancer; 2019 Apr; 19(1):326. PubMed ID: 30953473
[TBL] [Abstract][Full Text] [Related]
3. Level of N6-Methyladenosine in Peripheral Blood RNA: A Novel Predictive Biomarker for Gastric Cancer.
Ge L; Zhang N; Chen Z; Song J; Wu Y; Li Z; Chen F; Wu J; Li D; Li J; Wang C; Wang H; Wang J
Clin Chem; 2020 Feb; 66(2):342-351. PubMed ID: 32040577
[TBL] [Abstract][Full Text] [Related]
4. METTL14 promotes the migration and invasion of breast cancer cells by modulating N6‑methyladenosine and hsa‑miR‑146a‑5p expression.
Yi D; Wang R; Shi X; Xu L; Yilihamu Y; Sang J
Oncol Rep; 2020 May; 43(5):1375-1386. PubMed ID: 32323801
[TBL] [Abstract][Full Text] [Related]
5. RNA N6-methyladenosine demethylase FTO promotes breast tumor progression through inhibiting BNIP3.
Niu Y; Lin Z; Wan A; Chen H; Liang H; Sun L; Wang Y; Li X; Xiong XF; Wei B; Wu X; Wan G
Mol Cancer; 2019 Mar; 18(1):46. PubMed ID: 30922314
[TBL] [Abstract][Full Text] [Related]
6. Peripheral Blood Leukocyte N6-methyladenosine is a Noninvasive Biomarker for Non-small-cell Lung Carcinoma.
Pei Y; Lou X; Li K; Xu X; Guo Y; Xu D; Yang Z; Xu D; Cui W; Zhang D
Onco Targets Ther; 2020; 13():11913-11921. PubMed ID: 33239892
[TBL] [Abstract][Full Text] [Related]
7. FTO, PIK3CB serve as potential markers to complement CEA and CA15-3 for the diagnosis of breast cancer.
Mi J; Zhang H; Cao W; Yuan C
Medicine (Baltimore); 2023 Oct; 102(42):e35361. PubMed ID: 37861518
[TBL] [Abstract][Full Text] [Related]
8. METTL14-mediated N6-methyladenosine modification of SOX4 mRNA inhibits tumor metastasis in colorectal cancer.
Chen X; Xu M; Xu X; Zeng K; Liu X; Pan B; Li C; Sun L; Qin J; Xu T; He B; Pan Y; Sun H; Wang S
Mol Cancer; 2020 Jun; 19(1):106. PubMed ID: 32552762
[TBL] [Abstract][Full Text] [Related]
9. m6A RNA methylation regulators can contribute to malignant progression and impact the prognosis of bladder cancer.
Chen M; Nie ZY; Wen XH; Gao YH; Cao H; Zhang SF
Biosci Rep; 2019 Dec; 39(12):. PubMed ID: 31808521
[TBL] [Abstract][Full Text] [Related]
10. Glucose Is Involved in the Dynamic Regulation of m6A in Patients With Type 2 Diabetes.
Yang Y; Shen F; Huang W; Qin S; Huang JT; Sergi C; Yuan BF; Liu SM
J Clin Endocrinol Metab; 2019 Mar; 104(3):665-673. PubMed ID: 30137347
[TBL] [Abstract][Full Text] [Related]
11. Elevated N6-Methyladenosine RNA Levels in Peripheral Blood Immune Cells: A Novel Predictive Biomarker and Therapeutic Target for Colorectal Cancer.
Xie J; Huang Z; Jiang P; Wu R; Jiang H; Luo C; Hong H; Yin H
Front Immunol; 2021; 12():760747. PubMed ID: 34659267
[TBL] [Abstract][Full Text] [Related]
12. Expression profiles and prognostic roles of m6A writers, erasers and readers in gastric cancer.
Jing JJ; Zhao X; Li H; Sun LP; Yuan Y
Future Oncol; 2021 Jul; 17(20):2605-2620. PubMed ID: 33878934
[TBL] [Abstract][Full Text] [Related]
13. Prognostic implications of N
Tai J; Wang L; Guo H; Yan Z; Liu J
Sci Rep; 2022 Jan; 12(1):1222. PubMed ID: 35075167
[TBL] [Abstract][Full Text] [Related]
14. N6-Methyladenosine RNA modification in cerebrospinal fluid as a novel potential diagnostic biomarker for progressive multiple sclerosis.
Ye F; Wang T; Wu X; Liang J; Li J; Sheng W
J Transl Med; 2021 Jul; 19(1):316. PubMed ID: 34294105
[TBL] [Abstract][Full Text] [Related]
15. Circulating lncRNA H19 in plasma as a novel biomarker for breast cancer.
Zhang K; Luo Z; Zhang Y; Zhang L; Wu L; Liu L; Yang J; Song X; Liu J
Cancer Biomark; 2016 Jun; 17(2):187-94. PubMed ID: 27540977
[TBL] [Abstract][Full Text] [Related]
16. Increased N6-methyladenosine causes infertility is associated with FTO expression.
Ding C; Zou Q; Ding J; Ling M; Wang W; Li H; Huang B
J Cell Physiol; 2018 Sep; 233(9):7055-7066. PubMed ID: 29384212
[TBL] [Abstract][Full Text] [Related]
17. Signatures and Prognostic Values of N6-methyladenosine (m6A) - related Immune Genes in Bladder Cancer.
Lin G; Zhang J; Wu Y; Zhu S; Li G
Bioengineered; 2021 Dec; 12(1):2649-2663. PubMed ID: 34116604
[TBL] [Abstract][Full Text] [Related]
18. N6-methyladenosine methyltransferase plays a role in hypoxic preconditioning partially through the interaction with lncRNA H19.
Su Y; Xu R; Zhang R; Qu Y; Zuo W; Ji Z; Geng H; Pan M; Ma G
Acta Biochim Biophys Sin (Shanghai); 2020 Dec; 52(12):1306-1315. PubMed ID: 33197240
[TBL] [Abstract][Full Text] [Related]
19. Immune infiltration-related N6-methyladenosine RNA methylation regulators influence the malignancy and prognosis of endometrial cancer.
Ma J; Yang D; Ma XX
Aging (Albany NY); 2021 Jun; 13(12):16287-16315. PubMed ID: 34230220
[TBL] [Abstract][Full Text] [Related]
20. Identification of three m6A-related mRNAs signature and risk score for the prognostication of hepatocellular carcinoma.
Li Z; Li F; Peng Y; Fang J; Zhou J
Cancer Med; 2020 Mar; 9(5):1877-1889. PubMed ID: 31943856
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
